Australian Meningococcal Surveillance Programme Annual Report, 2022
Communicable Diseases Intelligence · 2023
DOI: 10.33321/cdi.2023.47.44 ↗Kurz gefasst
Fachartikel in der Zeitschrift Communicable Diseases Intelligence, 2023. Verfasst von Monica M Lahra und 3 weiteren Autor:innen. Beteiligte Einrichtung: World Health Organisation Collaborating Centre for STI and AMR, Sydney and Neisseria Reference Laboratory, Department of Microbiology, NSW Health Pat…. Hauptthemen laut MEDLINE: Neisseria meningitidis, Meningococcal Infections. Die Arbeit wurde bisher 3-mal zitiert (Crossref).
Abstract (Originalsprache)
In Australia, both probable and laboratory-confirmed cases of invasive meningococcal disease (IMD) are reported to the National Notifiable Diseases Surveillance System (NNDSS). Compared to 2021, the number of IMD notifications in 2022 increased by 81% to 127, alongside the easing of COVID-19 containment measures. Laboratory confirmation occurred in 95% of these cases, with 51% (62/121) diagnosed by bacterial culture and 49% (59/121) by nucleic acid amplification testing. The serogroup was determined for 97% of laboratory-confirmed cases (117/121): serogroup B (MenB) accounted for 83% of infections (100/121); MenW for 4% (5/121); MenY for 10% (12/121); no infections were attributed to MenC disease. Fine typing was available on 67% of the cases for which the serogroup was determined (78/117). In MenB isolates, 27 porA types were detected, the most prevalent of which were P1.7-2,4 (18%;11/62), P1.22,14 (15%; 9/62), P1.18-1,34 (10%; 6/62) and P1.7,16-26 (10%; 6/62). All five MenW infections identified as porA type P1.5,2 with different MLST sequence types (ST): 11, 574, 1287, 12351, 13135 all belonging to clonal complex 11, the hypervirulent strain reported in outbreaks in Australia and overseas. In MenY, the predominant porA type was P1.5-1,10-1 (73%; 8/11), ST 1655 and from clonal complex 23. Children less than 5 years of age and people aged 15–19 years were overrepresented with IMD notifications, accounting for 22% (27/121) and 23% (28/121) of laboratory-confirmed cases respectively. Fifteen percent of laboratory-confirmed notifications (18/121) were in persons aged 45–64 years. MenB infections were detected in all age groups but predominated in persons aged 15–19 years (93% of IMD in this age group; 26/28) and comprised 89% (24/27) of infections in children aged less than 5 years. MenW infections were markedly reduced in 2022, accounting for two IMD detections in children 1–4 years (2/16) and sporadic detections in other older age groups. MenY infections were largely detected in adults aged 45–64 years, accounting for 28% of IMD in this age group (5/18). All 62 cultured IMD isolates had antimicrobial susceptibility testing performed. Minimum inhibitory concentration (MIC) values were categorised using Clinical Laboratory Standards Institute (CLSI) interpretative criteria: 5% (3/62) were defined as penicillin resistant (MIC value ≥ 0.5 mg/L); 71% (44/62) had intermediate susceptibility to penicillin (MIC values 0.125 and 0.25 mg/L) and 24% (15/62) were susceptible to penicillin. All isolates were susceptible to ceftriaxone, ciprofloxacin and rifampicin.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- World Health Organisation Collaborating Centre for STI and AMR, Sydney and Neisseria Reference Laboratory, Department of Microbiology, NSW Health Pathology, The Prince of Wales Hospital, Randwick, 2031, NSW Australia; S…
- NSW Health Pathology, John Hunter Hospital, Newcastle, 2300, NSW Australia.
- New South Wales Health Pathology, Microbiology, Royal Prince Alfred Hospital Camperdown, NSW, Australia; School of Medicine, University of Sydney.
- World Health Organisation Collaborating Centre for STI and AMR, Sydney and Neisseria Reference Laboratory, Department of Microbiology, NSW Health Pathology, The Prince of Wales Hospital, Randwick, 2031, NSW Australia.
Zitieren
APA
Lahra, M. M., George, C. R., Van Hal, S., & Hogan, T. R. (2023). Australian Meningococcal Surveillance Programme Annual Report, 2022. Communicable Diseases Intelligence. https://doi.org/10.33321/cdi.2023.47.44
Vancouver
Lahra MM, George CR, Van Hal S, Hogan TR. Australian Meningococcal Surveillance Programme Annual Report, 2022. Communicable Diseases Intelligence. 2023. doi:10.33321/cdi.2023.47.44
BibTeX
@article{Lahra2023,
author = {Lahra, Monica M and George, CR Robert and Van Hal, Sebastiaan and Hogan, Tiffany R},
title = {Australian Meningococcal Surveillance Programme Annual Report, 2022},
journal = {Communicable Diseases Intelligence},
year = {2023},
doi = {10.33321/cdi.2023.47.44}
}
EUVIMED